Mylan NV swung to a loss as costs to overhaul operations at a West Virginia plant and continued sales declines weighed on the drugmaker in the latest period—along with the prospect of an expanding price-fixing probe. The stock tumbled about 24% on Tuesday to $21.53 on the weaker-than-expected start to the year—coupled with the company’s disclosure that multiple state attorneys general plan on filing a new complaint as part of a probe into whether drugmakers colluded to fix prices on generic treatments.

Source: Wall Street Journal May 07, 2019 18:33 UTC